Strides Pharma Science Limited

NSE:STAR.NS

1467.6 (INR) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q42014 Q32014 Q22014 Q1
Revenue 12,011.110,875.0510,840.3510,376.689,994.279,299.949,863.78,648.468,970.979,400.748,178.247,943.937,214.736,883.668,437.788,320.227,935.587,817.975,234.157,324.47,150.96,8587,531.967,9457,326.36,634.66,641.57,490.49,9568,417.78,884.18,762.99,221.78,446.29,243.214,465.3493,508.8415,8403,113.5123,143.7392,652.3462,410.612
Cost of Revenue 4,979.216,812.086,651.544,212.424,180.923,849.464,006.993,674.973,870.874,716.025,084.464,010.993,246.653,490.744,475.023,505.753,084.483,022.553,081.522,610.82,9893,158.54,286.033,827.23,522.53,404.42,927.93,495.44,8374,193.23,843.54,0214,001.54,0014,846.77,330.4491,769.143,058.41,471.7411,600.1721,303.121,229.787
Gross Profit 7,031.894,062.974,188.816,164.265,813.355,450.485,856.714,973.495,100.14,684.723,093.783,932.943,968.083,392.923,962.764,814.474,851.14,795.422,152.634,713.64,161.93,699.53,245.934,117.83,803.83,230.23,713.63,9955,1194,224.55,040.64,741.95,220.24,445.24,396.57,134.91,739.7012,781.61,641.7711,543.5671,349.2261,180.825
Gross Profit Ratio 0.5850.3740.3860.5940.5820.5860.5940.5750.5690.4980.3780.4950.550.4930.470.5790.6110.6130.4110.6440.5820.5390.4310.5180.5190.4870.5590.5330.5140.5020.5670.5410.5660.5260.4760.4930.4960.4760.5270.4910.5090.49
Reseach & Development Expenses 000000715.9900020024022002942852802471,039.652642552501,285.83002901,795.13038001,705.220001,054.06000393.9000
General & Administrative Expenses 0000002,322.80002,019.650001,816.430001,283.68000182.870001,134.7000-221.56000135.493000619.727000
Selling & Marketing Expenses 000000221.73000178.18000130.48000110.82000223.02000777.22000466.3000307.77000178.81000
SG&A 2,479.682,379.12,389.072,381.212,282.782,109.242,544.531,999.962,341.532,336.222,197.831,847.462,495.312,332.861,946.911,283.51,383.141,297.831,394.51,116.41,097971.3405.891,060.21,187.51,053.61,911.921,177.71,577.31,464.6244.741,548.21,906.21,650.5443.2631,308.237550.432478.42798.537412.809389.707392.627
Other Expenses 5,179.06127.16-135.4687.54358.4886.454,910.434,412.284,875.464,776.823,269.67101.89222.1135.32-265.29132.03128.71123.05-237.53122.2129.9102.5-56.158.377.3106.4218156.7222.7360.7730.5576.4313309.5278.4680.349191.222290.4-243.81444.187217.4260
Operating Expenses 5,179.062,379.12,389.074,738.434,883.134,380.464,910.434,412.284,875.464,776.823,269.674,495.854,544.454,495.262,8823,745.53,806.913,776.631,716.083,339.93,1162,892.32,096.863,253.63,252.72,851.13,291.83,1574,350.23,862.84,000.33,572.44,0323,586.43,732.66,093.3051,284.2632,381.3944.7871,045.4381,037.639804.991
Operating Income 1,852.831,683.871,799.741,074.86876.39801.69809.43-365.16-312.14-430.98.01-838.97-576.37-1,102.341,080.761,068.971,044.191,018.79436.551,373.71,045.9807.21,149.07864.2551.1379.1421.8838768.8361.71,040.31,169.51,188.2858.8663.91,041.595455.438400.3696.984498.129311.587291.248
Operating Income Ratio 0.1540.1550.1660.1040.0880.0860.082-0.042-0.035-0.0460.001-0.106-0.08-0.160.1280.1280.1320.130.0830.1880.1460.1180.1530.1090.0750.0570.0640.1120.0770.0430.1170.1330.1290.1020.0720.0720.130.0690.2240.1580.1170.121
Total Other Income Expenses Net -704.19-714.1-1,017.73-974.74-2,445.36-798.5-876.51-415-68.58-1,203.14-1,033.23-472.39-1,171.09-1,338.75-520.11-609.66-361.0132.46-2,615.15-337.4358.4-522.4-600.42-554.8-604.4-463.3-505.3-436.6-587.7-337.3128.5874.5-180.5-440.9-233-389.934-136.591-209.6-8,800.618-45.084172.012-19.772
Income Before Tax 1,148.64969.77782.01100.12-1,568.973.19-67.08-780.16-380.72-1,634.04-1,025.22-1,311.36-1,747.46-2,441.09560.65459.31683.181,051.25-2,178.61,036.31,404.3284.8548.65309.4-53.3-84.2-83.5401.4181.124.41,168.82,0441,007.7417.9430.9651.661318.847190.7-8,103.634453.045483.599271.476
Income Before Tax Ratio 0.0960.0890.0720.01-0.1570-0.007-0.09-0.042-0.174-0.125-0.165-0.242-0.3550.0660.0550.0860.134-0.4160.1410.1960.0420.0730.039-0.007-0.013-0.0130.0540.0180.0030.1320.2330.1090.0490.0470.0450.0910.033-2.6030.1440.1820.113
Income Tax Expense 212.03168.61192.51101.02-74.4296.7970.8740.9-384.04-280.74-1,314.81-44.78-67.64-355.4114.9107.7461.0432.83-104.7711373.831.2110.5263.316.1-42.7-39.5-1.641.6-33.4174.681152.492.2195.9134.224129.5975.5-721.928263.59460.92681.619
Net Income 932.32702.02181.75496.67-1,313.43-71.13-137.95-821.063.32-1,353.3292.19-1,216.71-1,625.59-2,052460.86378.47809.451,035.64-2,039.19938.91,427.237394.482,964.3-120.1-59.15,767.1825.975.95.61,123.21,873.2740.9260.4155.8518.639189.795106.2113.972190.437-425.57189.857
Net Income Ratio 0.0780.0650.0170.048-0.131-0.008-0.014-0.0950-0.1440.036-0.153-0.225-0.2980.0550.0450.1020.132-0.390.1280.20.0050.0520.373-0.016-0.0090.8680.110.0080.0010.1260.2140.080.0310.0170.0360.0540.0180.0370.061-0.160.079
EPS 10.147.641.98-0.49-14.54-0.79-1.53-9.090.037-15.073.25-13.55-18.12-22.885.144.229.0311.56-22.7710.4815.940.414.432.77-1.34-0.6663.459.550.960.0612.575.027.792.9120.965.524.441.341.273.2-4.753.18
EPS Diluted 10.127.621.97-0.49-14.54-0.79-1.53-9.090.037-15.073.25-13.55-18.12-22.885.144.229.0311.56-22.7710.4815.940.414.432.76-1.34-0.6663.439.540.960.0612.545.017.772.9120.935.514.431.321.273.19-4.753.18
EBITDA 2,475.372,169.812,297.341,587.141,477.441,397.591,418.72237.05304.88173.1614.77-130.98-368.49-609.431,188.621,829.721,622.551,991.19-371.281,897.81,180.91,111.2585.311,209.6933.7818.81,031.11,408.41,501.91,246.72,516.92,0702,063.11,519.81,604.62,302.775755.871985.8593.621666.799613.14404.21
EBITDA Ratio 0.2060.20.2120.1530.1480.150.1440.0270.0340.0180.075-0.016-0.051-0.0890.1410.220.2040.255-0.0710.2590.1650.1620.0780.1520.1270.1230.1550.1880.1510.1480.2830.2360.2240.180.1740.1590.2150.1690.1910.2120.2310.168